OBJECTIVE: The purpose of this study was to explore whether non-human leukocyte antigen (non-HLA) genetic markers can improve type 1 diabetes(T1D) prediction in a prospective cohort with high-risk HLA-DR,DQ genotypes. METHODS: The Diabetes Autoimmunity Study in the Young (DAISY) follows prospectively for the development of T1D and islet autoimmunity (IA)children at increased genetic risk. A total of 1709 non-Hispanic White DAISY participants have been genotyped for 27 non-HLA single nucleotide polymorphisms (SNPs) and one microsatellite. RESULTS: In multivariate analyses adjusting for family history and HLA-DR3/4 genotype, PTPN22 (rs2476601) and two UBASH3A (rs11203203 and rs9976767) SNPs were associated with development of IA [hazard ratio(HR)=1.87, 1.55, and 1.54, respectively, all p ≤ 0.003], while GLIS3 and IL2RA showed borderline association with development of IA. INS,UBASH3A, and IFIH1 were significantly associated with progression from IA to diabetes (HR=1.65, 1.44, and 1.47, respectively, all p ≤ 0.04), while PTPN22 and IL27 showed borderline association with progression from IA to diabetes. In survival analysis, 45% of general population DAISY children with PTPN22 rs2476601 TT or HLA-DR3/4 and UBASH3A rs11203203 AA developed diabetes by age 15, compared with 3% of children with all other genotypes (p<0.0001). Addition of non-HLA markers to HLA-DR3/4,DQ8 did not improve diabetes prediction in first-degree relatives. CONCLUSION: Addition of PTPN22 and UBASH3A SNPs to HLA-DR,DQ genotyping can improve T1D risk prediction. 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
OBJECTIVE: The purpose of this study was to explore whether non-human leukocyte antigen (non-HLA) genetic markers can improve type 1 diabetes(T1D) prediction in a prospective cohort with high-risk HLA-DR,DQ genotypes. METHODS: The Diabetes Autoimmunity Study in the Young (DAISY) follows prospectively for the development of T1D and islet autoimmunity (IA)children at increased genetic risk. A total of 1709 non-Hispanic White DAISY participants have been genotyped for 27 non-HLA single nucleotide polymorphisms (SNPs) and one microsatellite. RESULTS: In multivariate analyses adjusting for family history and HLA-DR3/4 genotype, PTPN22 (rs2476601) and two UBASH3A (rs11203203 and rs9976767) SNPs were associated with development of IA [hazard ratio(HR)=1.87, 1.55, and 1.54, respectively, all p ≤ 0.003], while GLIS3 and IL2RA showed borderline association with development of IA. INS,UBASH3A, and IFIH1 were significantly associated with progression from IA to diabetes (HR=1.65, 1.44, and 1.47, respectively, all p ≤ 0.04), while PTPN22 and IL27 showed borderline association with progression from IA to diabetes. In survival analysis, 45% of general population DAISY children with PTPN22 rs2476601 TT or HLA-DR3/4 and UBASH3Ars11203203 AA developed diabetes by age 15, compared with 3% of children with all other genotypes (p<0.0001). Addition of non-HLA markers to HLA-DR3/4,DQ8 did not improve diabetes prediction in first-degree relatives. CONCLUSION: Addition of PTPN22 and UBASH3A SNPs to HLA-DR,DQ genotyping can improve T1D risk prediction. 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Entities:
Keywords:
islet autoimmunity; non-HLA genetic markers; prediction; type 1 diabetes
Authors: Samy Mrena; Suvi M Virtanen; Pekka Laippala; Petri Kulmala; Marja-Leena Hannila; Hans K Akerblom; Mikael Knip Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Daniel B Mirel; Ana Maria Valdes; Laura C Lazzeroni; Rebecca L Reynolds; Henry A Erlich; Janelle A Noble Journal: Diabetes Date: 2002-11 Impact factor: 9.461
Authors: L Yu; M Rewers; R Gianani; E Kawasaki; Y Zhang; C Verge; P Chase; G Klingensmith; H Erlich; J Norris; G S Eisenbarth Journal: J Clin Endocrinol Metab Date: 1996-12 Impact factor: 5.958
Authors: M Rewers; T L Bugawan; J M Norris; A Blair; B Beaty; M Hoffman; R S McDuffie; R F Hamman; G Klingensmith; G S Eisenbarth; H A Erlich Journal: Diabetologia Date: 1996-07 Impact factor: 10.122
Authors: Brigitte I Frohnert; Lisa Ide; Fran Dong; Anna E Barón; Andrea K Steck; Jill M Norris; Marian J Rewers Journal: Diabetologia Date: 2017-03-17 Impact factor: 10.122
Authors: Brigitte I Frohnert; Michael Laimighofer; Jan Krumsiek; Fabian J Theis; Christiane Winkler; Jill M Norris; Anette-Gabriele Ziegler; Marian J Rewers; Andrea K Steck Journal: Pediatr Diabetes Date: 2017-07-11 Impact factor: 4.866
Authors: Andrea K Steck; Ping Xu; Susan Geyer; Maria J Redondo; Peter Antinozzi; John M Wentworth; Jay Sosenko; Suna Onengut-Gumuscu; Wei-Min Chen; Stephen S Rich; Alberto Pugliese Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Patrick M Carry; Lauren A Vanderlinden; Randi K Johnson; Fran Dong; Andrea K Steck; Brigitte I Frohnert; Marian Rewers; Ivana V Yang; Katerina Kechris; Jill M Norris Journal: Pediatr Diabetes Date: 2020-02-28 Impact factor: 4.866
Authors: Farah A Meah; Linda A DiMeglio; Carla J Greenbaum; Janice S Blum; Jay M Sosenko; Alberto Pugliese; Susan Geyer; Ping Xu; Carmella Evans-Molina Journal: Diabetologia Date: 2016-03-19 Impact factor: 10.122